Irvine-based Evolus Inc. priced its initial public offering of five million shares of common stock at $12 per share, the low end of an earlier-announced $12 to $14 range.
Cantor Fitzgerald & Co. and Mizuho Securities USA LLC are joint bookrunners. SunTrust Robinson Humphrey Inc. and JMP Securities LLC are lead managers.
Cantor and Mizuho have a 30-day option to purchase an additional 750,000 shares of common stock at the initial public offering price.
Evolus plans to list on the Nasdaq under the symbol EOLS.
Evolus develops a Botox-like compound used in facial aesthetic procedures that it licensed from Daewoong Pharmaceutical Co. Ltd. in Seoul. The product has undergone all clinical studies and been submitted for European and U.S. FOOD and Drug Administration approvals, according to filing.
Murthy Simhambhatla is chief executive of Evolus.
